Retatrutide vs Semaglutide
Three receptors against one — the widest mechanistic gap in the GLP-1 class.
The short answer: Semaglutide acts on GLP-1 alone; retatrutide adds GIP and glucagon.
Retatrutide
Semaglutide
Compound in Ozempic® · Wegovy®Side by side
| Property | Retatrutide | Semaglutide |
|---|---|---|
| Research category | Metabolic Research | Metabolic Research |
| Presentation | 4mg × 4 pens | 0.25mg × 4 pens |
| Dosage options | 4mg × 4 pens · 8mg × 4 pens · 12mg × 4 pens | 0.25mg × 4 pens · 1mg × 4 pens · 2.4mg × 4 pens |
| Approved medicine using it | None — investigational | Ozempic® · Wegovy® |
| Availability | In stock | In stock |
| Batch COA | Supplied with order | Supplied with order |
| From | €357.90 | €292.90 |
How they differ
Semaglutide is a single-receptor agonist: it targets GLP-1 and nothing else. Retatrutide targets GLP-1, GIP and the glucagon receptor. This is the largest mechanistic difference between any two compounds in this catalogue.
The practical consequence for research design is that semaglutide isolates one pathway cleanly, which makes it the more common reference compound. Retatrutide combines three, which complicates attributing an observed effect to any single receptor.
Semaglutide is the active compound in Ozempic and Wegovy and has years of published trial data behind it. Retatrutide is still in trials and has no approved formulation.
At the bench
Semaglutide is the reference compound in most of the GLP-1 literature, which makes it the easier of the two to design around — there is simply more to compare against. Retatrutide acting on three receptors makes attributing any observed effect to a single pathway substantially harder.
What this comparison does not settle
Adding receptors is not the same as adding effect. This comparison covers which receptors each binds, not how strongly, and binding affinity varies by receptor within a single molecule.
Common questions
What is the difference between Retatrutide and Semaglutide?
Semaglutide acts on GLP-1 alone; retatrutide adds GIP and glucagon. Three receptors against one — the widest mechanistic gap in the GLP-1 class.
Is Retatrutide or Semaglutide better?
Neither, and the question does not have a general answer. They are compared here on mechanism rather than merit. Adding receptors is not the same as adding effect. This comparison covers which receptors each binds, not how strongly, and binding affinity varies by receptor within a single molecule.
Which of the two has more published data?
Semaglutide. It is the compound behind Ozempic · Wegovy, so it carries a completed trial programme. Retatrutide remains investigational.
For research use only. Not for human consumption, diagnostic, therapeutic or veterinary use. Brand names are trademarks of their respective owners and are referenced only to identify the active compound — no affiliation or equivalence is claimed.